CN1272027C - Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method - Google Patents
Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method Download PDFInfo
- Publication number
- CN1272027C CN1272027C CN 03128126 CN03128126A CN1272027C CN 1272027 C CN1272027 C CN 1272027C CN 03128126 CN03128126 CN 03128126 CN 03128126 A CN03128126 A CN 03128126A CN 1272027 C CN1272027 C CN 1272027C
- Authority
- CN
- China
- Prior art keywords
- herba lysimachiae
- desmodium
- antiseptic
- adjuvant
- production method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000001883 cholelithiasis Diseases 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 201000001352 cholecystitis Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 241000522190 Desmodium Species 0.000 title abstract 9
- 208000004845 Cholecystolithiasis Diseases 0.000 title abstract 2
- 208000019206 urinary tract infection Diseases 0.000 title description 4
- 206010007027 Calculus urinary Diseases 0.000 title 1
- 208000009911 Urinary Calculi Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 17
- 230000002485 urinary effect Effects 0.000 claims abstract description 16
- 239000008187 granular material Substances 0.000 claims abstract description 13
- 239000006188 syrup Substances 0.000 claims abstract description 11
- 235000020357 syrup Nutrition 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 238000012856 packing Methods 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 235000008216 herbs Nutrition 0.000 claims description 15
- 230000002421 anti-septic effect Effects 0.000 claims description 14
- 235000008504 concentrate Nutrition 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 13
- 238000005520 cutting process Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 5
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 5
- 235000010234 sodium benzoate Nutrition 0.000 claims description 5
- 239000004299 sodium benzoate Substances 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 229960004365 benzoic acid Drugs 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 229960003885 sodium benzoate Drugs 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000009495 sugar coating Methods 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 16
- 239000002552 dosage form Substances 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 208000015924 Lithiasis Diseases 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 210000000941 bile Anatomy 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 8
- 210000000232 gallbladder Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241001571764 Lysimachia christinae Species 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 210000000013 bile duct Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 5
- 239000004575 stone Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000000014 Ureteral Calculi Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 4
- 230000001989 choleretic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- -1 flavone compounds Chemical class 0.000 description 4
- 208000031868 Calculus ureteric Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 3
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 206010061695 Biliary tract infection Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 241000222640 Polyporus Species 0.000 description 2
- 241000238370 Sepia Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- MQSZRBPYXNEFHF-UHFFFAOYSA-N rhamnocitrin Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C=C1 MQSZRBPYXNEFHF-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229960004016 sucrose syrup Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 description 1
- 241000612166 Lysimachia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000028484 Urethral disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 238000009606 cholecystography Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940056582 human hair preparation Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- MGYBYJXAXUBTQF-FSFUDZCRSA-N luteolin 7-O-rutinoside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C=C(Oc4c3)c5ccc(O)c(O)c5)[C@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@H]1O MGYBYJXAXUBTQF-FSFUDZCRSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a desmodium preparation for treating calculosis and infection of urinary systems, cholecystolithiasis and cholecystitis, particularly a desmodium tablet, a desmodium capsule, desmodium syrup or desmodium mixture and a production method thereof. The present invention has the production method that desmodium as a medicinal material is cut into segments (broken), cleaned and decocted in water for 2 to 3 times; decoction liquid is mixed and filtered; filter liquor is concentrated, and auxiliary materials are added to be made into granules or filled into capsules according to a compounding ratio by weight; or a certain amount of syrup or honey and preservatives are added, uniformly mixed and sub-packaged to obtain the desmodium syrup or the desmodium mixture. Compared with the existing granule (granular preparation), the novel dosage forms have the advantages of no moisture absorption, no agglomeration, long storage time, etc. The present invention brings convenience to drug stores, hospitals or patients.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, particularly treat the Herba Lysimachiae preparation and the production method thereof of urinary system calculus, infection and cholelithiasis, cholecystitis.
Background technology
Herba Lysimachiae is Primulaceae Lysimachia plant Lysimachia christinae Hance (Lysimachia christinae Hance), has another name called Herba Lysimachiae, to seat grass, LUBIANHUANG, Huang etc. everywhere, medicinal fresh or dry herb.Summer, Qiu Erji gather, and remove impurity, dry, and be standby.
The character of Herba Lysimachiae: this product is often tangled agglomerating, does not have hair or is dredged hair.Color or dark brownish red are pressed in stem distortion, surface, and longitudinal grin is arranged, and have fibrous root on the stipes of bottom sometimes, and section is solid.Leaf is to life, and many shrinkages are width egg shape or heart after the flattening, long 1～4cm, wide 1～5cm, base portion nick, full paper edge; Upper surface celadon or sepia, the following table complexion is more shallow, and the obvious projection of master pulse is after water logging, to x ray fluoroscopy x visible black color or brown striped; Long 1～the 4cm of petiole, what have is wounded in the battle, brightly yellowish color, single leave axil, the long stalk of tool.The capsule sphere.Feeble QI, lightly seasoned.
The discriminating of Herba Lysimachiae: isolate potassium chloride and mix saccharide in the some gland Lysimachia christinae Hance herb, preliminary examination still has flavonoid, Saponin, glycoside, lactone and organic acid etc.
The pharmacology of Herba Lysimachiae: select 5 milliliters of gland Lysimachia christinae Hance decocts rat every day oral 100%, serve on for 6 weeks, under general anesthesia acute experiment situation, with matched group relatively, have to promote to stop excretory effect.Lower or the phase of taking is short as dosage, then act on not obvious.Obeying decoct continuously after 2～3 days, the animal stool is thinning, and color becomes sepia, but does not find the chronic poisoning phenomenon.Rat does not have gallbladder, so promote biliary drainage, is not to cause by strengthening gallbladder contraction institute.The people is carried out cholecystography, also prove that Herba Lysimachiae can not make gallbladder shrink and strengthen.
The Herba Lysimachiae bitter in the mouth, acid is slightly cold.Return liver, gallbladder, kidney, urinary bladder channel.The function heat-clearing and toxic substances removing, diuresis and expelling stone, promoting blood circulation to remove blood stasis.Be used for liver, cholelithiasis, cholecystitis, icterohepatitis, urinary system calculus, edema, traumatic injury, venom, malicious Mus and drug intoxication: suppurative inflammation is controlled in external, burn and scald.Pass on from one to another Sichuan BAICAO hall proved recipe transcript, Qing Dynasty's qianlong years (1736-1795) has the record of Herba Lysimachiae treatment " yellow sand is walked cellulitis ", has had the applicating history in year surplus in the of 200 at least so far.Nearly 50 years, domestic scholars was carried out many researchs to chemical constituent, pharmacological action and the clinical practice of Herba Lysimachiae.
The preliminary analysis Herba Lysimachiae contains compositions such as phenolic constituent, flavonoid, glycoside, tannin, volatile oil, aminoacid, choline, sterol, potassium chloride, interior lipid.Wherein flavonoid research is more deep, has isolated 10 kinds of chemical compounds.Chinese science and technology periodical report from the ethanol extract of Herba Lysimachiae behind defat with petroleum ether, last polyamide column, water and 20%, 50%, 70%, 90% ethanol carries out processes such as low pressure column chromatography and gradient elution, obtain six flavone compounds, be respectively Quercetin (Quetcetin), quercetin glucoside, kaempferide (Kaempferol), the kaempferide galactoside, kaempferide three glucosides etc., ethanol extract to Herba Lysimachiae passes through the H-103 macroporous adsorptive resins, carry out the silica gel column layer folding again, carry out eluting, obtain four kinds of flavone compounds with different eluents, be respectively kaempferol-3-glycoside, kaempferol-3-rutinoside. rhamnocitrin diglucoside and afzelin-7-rhamanopyranosyl Mus-Lee's 1-3-glucoside etc.
According to the TCM Document introduction, Herba Lysimachiae has the cholagogic and lithagogue effect, and bibliographical information is arranged, and the Herba Lysimachiae decoct all has certain choleretic effect to rat, dog.Give rat oral gavage 5ml every day with Herba Lysimachiae decoct (1: 1), serve on 6w, anaesthetize after experiment day 3ml irritates stomach, biliary drainage, the result proves that it has obvious promotion bile secretion and Excretion, the drain of people's duodenum also shows that Herba Lysimachiae has choleretic effect.Since this nothing of rat gallbladder, think that the choleretic effect of Herba Lysimachiae is not to shrink by the reflexive gallbladder, and may be to promote the hepatocyte secretion of bile, bile increases in the bile duct, intrinsic pressure increasing, and Oddi's sphincter relaxes and gets rid of bile.Because choleretic effect is easily discharged bile duct silt shape calculus, bile duct occlusion and pain relief, jaundice disappears.The fresh bile that adopts bilins calculus patient to drain proves that as experiment in vitro Paishi Tang can stop bile mesobilin class component precipitation, and cholelithiasis is generated preventive effect.It is relevant that this effect and Paishi Tang obviously suppress in the bile beta-glucuronic acid glycoside activity.
Open source literature has been introduced the achievement in research of many Herba Lysimachiaes or Herba Lysimachiae mixture treatment urethra and gallstone disease at present, as " Guangxi Chinese medicine " 1990,13 (6) .40-41 " pharmacological evaluation of Herba Lysimachiae granule " have studied Herba Lysimachiae granule treatment urinary system calculus and analgesic effect; " journal of shanghai Chinese medicine " 2000,34 (2) .-30-31 " oral liquid treatment urinary system infection that money is treating stranguria " are for observing the treating stranguria oral liquid of money (Herba Lysimachiae, Folium Pyrrosiae, Spora Lygodii, Caulis Lonicerae, Rhizoma Imperatae) curative effect of treatment urinary system infection lower warmer wetness-heat type stranguria (acute cystitis, acute pyelonephritis, acute episode of chronic pyelonephritis) is according at random, double blinding, contrast method is divided into the treatment group, each 40 example of matched group (NIAOGANNING CHONGJI), and observing for 2 weeks is a course of treatment.Result: treatment group total effective rate 87.5%, no obvious adverse reaction; 65%, two group relatively there were significant differences (P＜0.05) for the matched group total effective rate; " capital medicine " .2000,7 (9) .30-31 " ofloxacin and Chinese medicine Herba Lysimachiae granule therapeutic alliance urinary tract infection are analyzed " adopt the therapy of combining Chinese and Western medicine method of ofloxacin and Herba Lysimachiae granule when treatment urinary tract infection disease, obtained effect preferably; Chinese patent＜application number〉00135843 " a kind of medicine for the treatment of urinary system calculus " disclose calculus in a kind of treatment kidney, pyelolithiasis, vesical calculus, urinary system calculus and hydronephrotic medicines such as ureteral calculi, this medicine are that the Chinese medicine by the following weight ratio is prepared from: the flat blood 10-15 of Herba Lysimachiae 30-60 Radix Salviae Miltiorrhizae 15-30 Spora Lygodii 20-30 Poria 15-20 Radix Glycyrrhizae 3-6 Radix Clematidis 20-30 Endothelium Corneum Gigeriae Galli 10-15 Radix Rehmanniae 15-25 Folium Pyrrosiae 15-25 Radix Bupleuri 10-15 cattle sunset 10-15 Rhizoma Imperatae 20-30 Semen Plantaginis 15-25 Fructus Aurantii 6-10 Semen Vaccariae 20-30 Herba Dianthi 15-25 succinum 10-15 Talcum 15-25 Medulla Tetrapanacis 5-10 Polyporus 15-25 Rhizoma Corydalis 10-15; Chinese patent＜application number〉00124371 " a kind of medicine for the treatment of lithangiuria and preparation method thereof " disclose a kind of medicine that is used for the treatment of lithangiuria, it selects Herba Lysimachiae grass, Herba Polygoni Perfoliati, Folium Pyrrosiae, Herba Polygoni Avicularis, Rhizoma Alismatis, Caulis Aristolochiae Manshuriensis, Polyporus, Rhizoma Imperatae, RADIX CURCUMAE from Sichuan of China, Poria, Pulvis Talci, potassium chloride for use, makes dosage forms such as pill, tablet, capsule.The effective percentage of treatment lithangiuria is 91.7%; Chinese patent＜application number〉97100244 " a kind of medicines for the treatment of urinary system calculus " disclose a kind of medicine for the treatment of urinary system calculus, it be with bright Ren sus domestica, Radix Rehmanniae, Rhizoma Dioscoreae, Cortex Moutan, Poria, Rhizoma Alismatis, Radix Achyranthis Bidentatae, Semen Plantaginis, Caulis Akebiae, Herba Dianthi, Talcum, Fructus Gardeniae, Radix Glycyrrhizae slightly, the oral drugs that are prepared from of Radix Et Rhizoma Rhei, Rhizoma Imperatae, Crinis Carbonisatus, Pollen Typhae, Folium Pyrrosiae, Spora Lygodii, Herba Lysimachiae, Natrii Sulfas, can be used for treating the diseases such as urine retention dysurea that renal calculus, ureteral calculus, vesical calculus, lithangiuria and prostate hyperplasia, inflammation cause.
See from open source literature, Herba Lysimachiae or be that the Chinese medicine preparation therapeutic effect of representative is apparent in view with the Herba Lysimachiae, but only developed electuary (granule) through the single Herba Lysimachiae of careful retrieval, also find no other dosage form and occur, Herba Lysimachiae granule (granule) needs to add sucrose mostly owing to be almost flour in actual applications, so be difficult for preserving, the easy moisture absorption, caking, the time of depositing is shorter, has brought trouble for pharmacy, hospital or patient.
Technology contents
The inventor is through studying and test pharmacology and the pharmacodynamics of Herba Lysimachiae, and analyzed the physicochemical characteristics of Herba Lysimachiae granule, think if Herba Lysimachiae is carried out the improvement of dosage form, can be to improving the useful effect of clinical generation of Herba Lysimachiae, so the inventor tests aspect the dosage form of Herba Lysimachiae, has made new dosage form.Technical scheme of the present invention is as follows:
The Herba Lysimachiae preparation of treatment urinary system calculus comprises money blade and Herba Lysimachiae capsule, Herba Lysimachiae syrup, Herba Lysimachiae mixture
The composition of described money blade and weight percentage are:
Herba Lysimachiae extract 50-90%
Adjuvant 10-50%
Described adjuvant comprises that starch, dextrin, magnesium stearate, calcium carbonate etc. meet the pharmaceutic adjuvant and the food additive of China's working standard.
The production method of money blade is as follows:
Depletion money medical herbs material, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and adds adjuvant by weight ratio, granulation, dry, tabletting, packing; Or sugar coating, or packing obtains product behind the bag film-coat.
Capsular composition of described Herba Lysimachiae and weight percentage are:
Herba Lysimachiae extract 85-90%
Adjuvant 10-15%
Said adjuvant comprises that starch, dextrin, magnesium stearate, differential silica gel etc. meet the pharmaceutic adjuvant and the food additive of China's working standard.Wherein select for use the amount of adjuvant to be: starch 10-30%, dextrin 10-20%, lubricant: magnesium stearate 0.5-1%, fluidizer differential silica gel 0.5-1%.
The capsular production method of Herba Lysimachiae is as follows:
Depletion money medical herbs material, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and adds adjuvant by weight ratio, makes granule, and drying adds lubricant or fluidizer is encapsulated, and packing obtains product.
Syrupy composition of described Herba Lysimachiae and weight percentage are:
Herba Lysimachiae extract 30-70%
Antiseptic 0.1-1%
The sucrose surplus
Said antiseptic is selected from potassium sorbate, ethyl hydroxybenzoate, benzoic acid, sodium benzoate.
The syrupy production method of Herba Lysimachiae is as follows:
Depletion money medical herbs material, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and concentrated solution is filtered, and adds sucrose, antiseptic dissolving, mix homogeneously, packing obtains product.
The composition of described Herba Lysimachiae mixture and weight percentage are:
Herba Lysimachiae extract 41-90%
Antiseptic 0.1-1%
Sucrose or Mel surplus
Said antiseptic is selected from potassium sorbate, ethyl hydroxybenzoate, benzoic acid, sodium benzoate.
The production method of Herba Lysimachiae mixture is as follows:
Depletion money medical herbs material, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and adds quantitative syrup or Mel and antiseptic, mix homogeneously, packing obtains product.
Acting on of the basic chemical constituent of Herba Lysimachiae of the present invention and treatment lithangiuria, liver and bile stone disease above-mentionedly is described, and below further specifies in conjunction with the novel formulation of money herb rubber capsule, Herba Lysimachiae syrup, Herba Lysimachiae mixture again:
Will note distinguishing the Herba Lysimachiae on the plant classification when at first selecting raw material, China various places are distributed with multiple Herba Lysimachiae, and the leguminous plant Herba Desmodii Styracifolii has diuresis, calculus, antiinflammation, for commonly using in Guangxi, Guangdong Province; The labiate Herba Glechomae is controlled urinary tract infection, falls damage, and the jaundice due to damp-heat effect is for commonly using in Zhejiang, Jiangsu; Also have and do that Herba Lysimachiae uses Flos Inulae section plant Herba Dichodrae (having another name called the lobule Herba Lysimachiae) arranged, clearing away heat and promoting diuresis, anti-inflammatory analgetic effect are arranged.
Primulaceae Lysimachia plant Lysimachia christinae Hance (Lysimachia christinae Hance) the Herba Lysimachiae nature and flavor that the present invention adopts with return through: sweet, salty, be slightly cold.Return liver, gallbladder, kidney, urinary bladder channel.Function is with to cure mainly heat clearing away damp and hot, treating stranguria, detoxifcation, detumescence.Be used for pyretic stranguria, the husky pouring, renal calculus, vesical calculus is urinated and is puckeryly had a pain jaundice dark coloured urine, carbuncle furuncle, venom, liver and bile stone, lithangiuria.
Below be several respects effect of the money blade for preparing of the present invention, Herba Lysimachiae capsule, Herba Lysimachiae syrup, Herba Lysimachiae mixture:
1, diuresis and expelling stone effect
Do experiment with anesthetized dog, behind the mixture that duodenum notes Herba Lysimachiae 120g makes, the enhancing ureteral peristalsis similar occur and increase the effect of urinating flow to hydrochlorothiazide. and two kinds of effects are parallel relation.Anesthetized dog intravenous injection Herba Lysimachiae extracting solution can cause hydrouria, and the ureteral peristalsis frequency increases, and simultaneously visible ureter epimere cavity pressure raises.So thinking, the inventor use Herba Lysimachiae treatment ureteral calculus to receive that lithagogue effect may be relevant with above-mentioned factor clinically.The result who observes in the influence of Calcium oxalate (CaC2O4) monohydrate crystallization rate with conductance method proves that the polysaccharide component in the alcohol-insoluble substances of Herba Lysimachiae has inhibitory action to the crystalline growth of Calcium oxalate (CaC2O4) monohydrate;
2, antiinflammatory action
Herba Lysimachiae is oozed out reaction to the anxious inflammation of animal and oozes out the inhibitory action that reaction all has highly significant with chronic.The mice vascular permeability that histamine is caused increases, rat arthroncus and granuloma induced by implantation of cotton pellets all have remarkable inhibitory action due to the mice ear inflammation due to the Oleum Tiglii, fresh albumen.Prove that also its antiinflammatory effective site is total flavones and phenolic acid thing.
3, bacteriostasis: the flat band method experiment shows that the Herba Lysimachiae mixture has inhibitory action to Diplococcus pneumoniae, and inhibiting in vitro tests shows to hepatitis B virus, and Herba Lysimachiae is the inhibitory action that can coagulate to HBsAG; Herba Lysimachiae also has inhibitory action to staphylococcus aureus.
4, analgesic activity
Bibliographical information proves all that with writhing method and hot plate method Herba Lysimachiae has certain analgesic activity.
Clinical practice
1, liver and gall diseases
Cholelithiasis
Treat 10 routine liver and bile stones with Herba Lysimachiae, receive significant curative effect.Total effective rate 80.5%, the effective percentage 92.8% of calculus of bile duct, cholelithiasis effective percentage 71.5%), the shortest person 60d of treatment time, elder 300d, average 98d.Use Chinese and Western and treat liver, sick 61 examples of calculus of bile duct, receive promising result in conjunction with general attack therapy.
2, biliary tract infection
Therapeutic outcome to non-bacterial biliary tract infection 52 examples shows that Herba Lysimachiae mixture 10-30g/d Instant Drinks are generally taken 2-3m, effective 40 examples, and total effective rate 76.9% has no side effect, and has no adverse reaction
The Herba Lysimachiae untoward reaction is less, and it is above without any side effects that the oral Herba Lysimachiae of 10 routine cholelithiasis patients 150-250g every day reaches half a year, and 10 examples reach 300d and also do not see toxicity.Other has report, and 1 routine ureteral calculus patient 1 jin of every day serve on 7d and has no adverse reaction.
The money blade that the present invention prepares, Herba Lysimachiae capsule, Herba Lysimachiae syrup, Herba Lysimachiae mixture are except having above-mentioned effect, compare with existing electuary (granule), also have the moisture absorption of being not easy, caking, the time of depositing has brought convenience for pharmacy, hospital or patient than advantages such as length.
The specific embodiment
Embodiment 1
Depletion money medical herbs material 2000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and again the 1000g concentrated solution is added food starch 200g, and magnesium stearate 100g mixes, granulation, dry, tabletting, packing; Packing obtains product behind the sugar coating.
Embodiment 2
Get the 1000g concentrated solution adding dextrin 100g that embodiment 1 obtains, calcium carbonate 100g, magnesium stearate 50g mixes, granulation, dry, tabletting, packing; Packing obtains product behind the bag film-coat.
Embodiment 3
Depletion money medical herbs material 5000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, filtrate is condensed into clear paste, again the 1000g clear paste is added starch 100g, dextrin 150g, magnesium stearate 50g, differential silica gel 80g, mix homogeneously, drying, encapsulated, packing obtains product.
Embodiment 4
Depletion money medical herbs material 5000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, filtrate is condensed into clear paste, again the 1000g clear paste is added starch 300g, dextrin 180g, magnesium stearate 100g, differential silica gel 100g, mix homogeneously, drying, encapsulated, packing obtains product.
Embodiment 5
Depletion money medical herbs material 2000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and concentrated solution is filtered, and again the 300g concentrated solution is added potassium sorbate 8g, sucrose syrup 700g, mix homogeneously, packing obtains product.
Embodiment 6
Depletion money medical herbs material 2000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and concentrated solution is filtered, and again the 700g concentrated solution is added ethyl hydroxybenzoate 5g, sucrose syrup 300g, mix homogeneously, packing obtains product.
Embodiment 7
Depletion money medical herbs material 2000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and concentrated solution is filtered, and again the 500g concentrated solution is added sorbitol 10g, sucrose 500g, mix homogeneously, packing obtains product.
Embodiment 8
Depletion money medical herbs material 2000g, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and concentrated solution is filtered, and again the 600g concentrated solution is added sodium benzoate 3g, Mel 400g, mix homogeneously, packing obtains product.
Claims (4)
1, a kind of Herba Lysimachiae tablet for the treatment of urinary system calculus, infection and cholelithiasis, cholecystitis is characterized in that: this Herba Lysimachiae tablet is to be made by the Herba Lysimachiae extract and the adjuvant of following weight percentage:
Herba Lysimachiae extract 50-90%
Adjuvant 10-50%
Said adjuvant comprises starch, dextrin, magnesium stearate, calcium carbonate;
The production method of described money blade is as follows:
Depletion money medical herbs material, chopping cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and adds adjuvant by weight ratio, granulation, dry, tabletting, packing; Or sugar coating, or packing obtains product behind the bag film-coat.
2, a kind of Herba Lysimachiae capsule for the treatment of urinary system calculus, infection and cholelithiasis, cholecystitis is characterized in that: this Herba Lysimachiae capsule is to be made by the Herba Lysimachiae extract and the adjuvant of following weight percentage:
Herba Lysimachiae extract 85-90%
Adjuvant 10-15%
Said adjuvant comprises starch, dextrin, magnesium stearate, differential silica gel;
The capsular production method of described Herba Lysimachiae is as follows:
Depletion money medical herbs material, cutting (broken) cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and adds adjuvant by weight ratio, makes granule, and drying adds lubricant or fluidizer is encapsulated, and packing obtains product.
3, a kind of Herba Lysimachiae syrup for the treatment of urinary system calculus, infection and cholelithiasis, cholecystitis is characterized in that: this Herba Lysimachiae syrup is to be made by the Herba Lysimachiae extract of following weight percentage and antiseptic, sucrose:
Herba Lysimachiae extract 30-70%
Antiseptic 0.1-1%
The sucrose surplus
Said antiseptic is selected from potassium sorbate, ethyl hydroxybenzoate, benzoic acid, sodium benzoate;
The syrupy production method of described Herba Lysimachiae is as follows:
Depletion money medical herbs material, chopping cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and concentrated solution is filtered, and adds sucrose, antiseptic dissolving, mix homogeneously, packing obtains product.
4, a kind of Herba Lysimachiae mixture for the treatment of urinary system calculus, infection and cholelithiasis, cholecystitis is characterized in that: this Herba Lysimachiae mixture is to be made by the Herba Lysimachiae extract of following weight percentage and antiseptic, sucrose or Mel:
Herba Lysimachiae extract 41-90%
Antiseptic 0.1-1%
Sucrose or Mel surplus
Said antiseptic is selected from potassium sorbate, ethyl hydroxybenzoate, benzoic acid, sodium benzoate;
The production method of described Herba Lysimachiae mixture is as follows: depletion money medical herbs material, and chopping cleans up, and decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and adds quantitative syrup or Mel and antiseptic, mix homogeneously, packing obtains product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03128126 CN1272027C (en) | 2003-06-06 | 2003-06-06 | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03128126 CN1272027C (en) | 2003-06-06 | 2003-06-06 | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1478515A CN1478515A (en) | 2004-03-03 |
| CN1272027C true CN1272027C (en) | 2006-08-30 |
Family
ID=34153244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03128126 Ceased CN1272027C (en) | 2003-06-06 | 2003-06-06 | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1272027C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360144C (en) * | 2005-11-03 | 2008-01-09 | 龙万春 | Chinese medicine for treating urinary tract lithiasis and its prepn |
| CN101352481B (en) * | 2008-09-05 | 2011-03-02 | 浙江省医学科学院 | Method for preparing Chinese medicine desmodium anti-calculi fractionated extracts and uses thereof |
| CN102973647A (en) * | 2012-12-20 | 2013-03-20 | 广西健丰药业有限公司 | Preparation method and quality control method of sugar-free stranguria-treating and calculus-removing particles |
| CN104069140B (en) * | 2014-07-23 | 2017-06-30 | 重庆和平制药有限公司 | A kind of method for preparing desmodium medicinal extract and its particle |
| CN104224867B (en) * | 2014-09-28 | 2017-08-08 | 重庆和平制药有限公司 | A kind of desmodium sugar-free particle and preparation method thereof |
| CN113633622B (en) * | 2021-08-20 | 2022-07-05 | 浙江维康药业股份有限公司 | Herba lysimachiae capsule and preparation method thereof |
| CN115554332A (en) * | 2021-12-17 | 2023-01-03 | 吉林省正和药业集团股份有限公司 | Lysimachia christinae hance tablet and preparation method thereof |
-
2003
- 2003-06-06 CN CN 03128126 patent/CN1272027C/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1478515A (en) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN101757591B (en) | Traditional Chinese medicine composition for treating chronic colitis and protitis | |
| CN1272027C (en) | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method | |
| CN104840695A (en) | Medicine combination for treating white scour of piglet and preparation method thereof | |
| CN105250954B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN105214032A (en) | The solid dispersion tablet for the treatment of peptic ulcer | |
| CN1207054C (en) | Chinese medicine for treating pelvis, nephritis and kidney injury and preparing method thereof | |
| CN105250946A (en) | Solid dispersion for treating peptic ulcers | |
| CN105214037A (en) | The solid dispersal capsule for the treatment of peptic ulcer | |
| CN105233201A (en) | Solid dispersible granules for treating peptic ulcers | |
| CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
| CN105214035A (en) | One treats peptic ulcer tablet and preparation method thereof | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN1475243A (en) | External medicine for treating leucoderma | |
| CN1242772C (en) | Chinese medicine for hemorrhoid | |
| CN1277559C (en) | Medicine for treating rheumatism and its preparation | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN1064536C (en) | Full-divergence promoting medicine for curing fourth-phase carcinoma of stomach and its processing method | |
| CN1634357A (en) | A traditional Chinese medicinal lotion for treating gynecological inflammation | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
| CN105194608A (en) | Micro-powder capsule for treating peptic ulcers | |
| CN105250951A (en) | Preparing method for medicine for treating peptic ulcer | |
| CN104887825A (en) | Traditional Chinese medicine prescription for curing eczema and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C35 | Partial or whole invalidation of patent or utility model | ||
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20090831 Decision number of declaring invalidation: 13780 Granted publication date: 20060830 |